I've been ordering from WWB since Q2 2024 and I'm now sitting on 14 Janoshik HPLC results spanning nearly two years. Figured it's time to do a longitudinal quality analysis for the community. Semaglutide 10mg — Janoshik HPLC Results: | Date | Batch | Purity | |------|-------|--------| | Apr 2024 | S-2404 | 97.2% | | Jun 2024 | S-2406 | 97.8% | | Aug 2024 | S-2408 | 98.1% | | Oct 2024 | S-2410 | 97.5% | | Jan 2025 | S-2501 | 98.6% | | Mar 2025 | S-2503 | 98.9% | | Jun 2025 | S-2506 | 99.1% | | Sep 2025 | S-2509 | 98.7% | | Dec 2025 | S-2512 | 99.0% | | Feb 2026 | S-2602 | 99.4% | Tirzepatide 30mg — Janoshik HPLC Results: | Date | Batch | Purity | |------|-------|--------| | Jul 2024 | T-2407 | 96.8% | | Nov 2024 | T-2411 | 97.4% | | Mar 2025 | T-2503 | 98.2% | | Aug 2025 | T-2508 | 98.6% | Key Observations: 1. Clear upward trend in purity across both products over the two-year window 2. Semaglutide went from ~97% range to consistently 99%+ 3. Tirzepatide improved from sub-97% to 98%+ 4. No single batch tested below 96.8% 5. Variance has decreased — the last four sema tests span only 0.7% (98.7-99.4%) My interpretation: WWB has been actively improving their synthesis and purification processes. The early 2024 batches were "good enough" but not exceptional. By late 2025/early 2026, they're producing pharma-adjacent purity levels. This is consistent with a maturing operation investing in better HPLC columns, optimized solvent systems, and tighter process controls. Thoughts?

This is exactly the kind of longitudinal data the community needs. 14 data points over two years from a single buyer eliminates the "different testing conditions" variable that makes cross-person comparisons noisy. The upward trend is statistically significant even with this sample size. If I run a simple linear regression on your sema data, R-squared is about 0.87 — that's a strong positive correlation with time. Not just random variance, there's a real improvement signal. One question: did you always use the same Janoshik test panel? They've updated their methods a couple times. If the early tests used a different HPLC column or gradient, that could partially explain lower readings (not the whole story, but a confound worth noting).

Good catch. Janoshik did update their analytical method in late 2024 — they switched to a newer C18 column and adjusted their acetonitrile gradient. However, the transition happened around October 2024, and you can see the upward trend continues consistently after that transition point. So while there might be a small systematic effect from the method change, the improvement trend is present within both the old-method and new-method data subsets. I also sent two samples from the same vial for the Feb 2026 batch and got 99.4% and 99.3% — so the test-retest reproducibility is tight.

I've been in this space since the early 2020s when grey market peptides were mostly growth hormone secretagogues and research chemicals. The quality trajectory you're showing for WWB is actually typical of Chinese peptide suppliers that survive and grow. The pattern: they enter the market with "good enough" purity (95-97%), establish a customer base, then reinvest profits into better equipment and process optimization. The ones that don't improve either stagnate and lose customers or exit the market. What's unusual about WWB is the *speed* of improvement. Going from 96.8% to 99.4% in two years is faster than most suppliers I've tracked. Could indicate significant capital investment in their production line. Or they switched to a better upstream raw material supplier. Either way, good for us.

Counterpoint: I ordered from a different Chinese vendor (not naming names) that showed a similar upward quality trajectory for about 18 months... then quality dropped sharply when they presumably switched to a cheaper synthesis route to maintain margins as raw material costs increased. Not saying this will happen with WWB. But past performance doesn't guarantee future results. The community needs to keep testing regularly, not just assume the trend continues. A vendor could get complacent or face cost pressures at any time. The best protection is ongoing independent verification. Every 3rd or 4th order, send a vial to Janoshik. It's cheap insurance.